

ORAL PRESENTATION

Open Access

Melanoma-intrinsic β -catenin signaling prevents T cell infiltration and anti-tumor immunity

Stefani Spranger*, Riyue Bao, Thomas Gajewski

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

A subset of melanoma patients has evidence for spontaneous anti-tumor immune responses and T cell infiltration into tumor sites, which has important prognostic value and is associated with clinical responses to immunotherapies. However, the molecular mechanisms explaining absence of a T cell response in the majority of patients are not defined. Analyses of human melanoma metastases by exome sequencing, gene expression profiling, and IHC have revealed that many tumors that lack a T cell signature show alterations in the Wnt/ β -catenin signaling pathway. To investigate if constitutively active β -catenin signaling within the tumor cells might inhibit immune responses, we utilized an inducible autochthonous mouse melanoma model driven by inducible Braf^{V600E} and PTEN-deletion, with or without inducible expression of active β -catenin. While Braf/PTEN melanomas showed presence of a modest T cell infiltrate, T cells were nearly completely eliminated in tumors expressing active β -catenin. The T cells that were present in the Braf/PTEN tumors showed an exhausted phenotype as what has been seen in transplanted tumor models, and therapeutic efficacy of combination therapy using α CTLA4 with α PD-L1 mAbs was limited to Braf/PTEN tumors. To test whether the lack of T cell infiltration was due to a defect in early T cell priming, these mice were additionally bred to inducibly express the SIY model antigen within the developing tumors. Adoptive transfer of 2C TCR Tg SIY-specific T cells revealed defective spontaneous T cell priming when tumors expressed active β -catenin. Analysis of the antigen-presenting cell compartment revealed a selective decrease in the CD103⁺ DC subset within the tumor microenvironment, and T cell infiltration could be restored by intra-tumoral injection of FLT3-ligand-derived dendritic cells. The lack of CD103⁺ dermal dendritic cells was associated with reduced expression of the chemokines

CCL4 and CXCL1. Surprisingly we identified that tumor cells themselves as the major chemokine source in Braf/PTEN tumors, while tumors with active β -catenin signaling lacked expression of those chemokines. Therefore, our data have identified the first defined molecular pathway in tumor cells that results in defective spontaneous anti-tumor T cell responses, an observation with important implications for cancer immunotherapy.

Consent

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-O15

Cite this article as: Spranger et al.: Melanoma-intrinsic β -catenin signaling prevents T cell infiltration and anti-tumor immunity. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):O15.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



University of Chicago, Chicago, IL, USA



© 2014 Spranger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.